Avadel Pharmaceuticals: Moving Nicely Through An 'Inflection Year' (NASDAQ:AVDL) - Seeking Alpha
5 days ago • Google News
Avadel Pharmaceuticals PLC (AVDL)
US$ 8.894.22%
Price Chart
Key Statistics
Market Cap
$ 904.51M
P/E Ratio
0.00
Revenue (TTM)
$ 194.45M
Volume
912.23K
52W High
$ 17.30
52W Low
$ 6.38
Dividend Yield
0.00%
Beta
1.63
Technicals
50-Day MA
8.2914
200-Day MA
10.9303
52 Week High
17.298
52 Week Low
6.38
About AVDL
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial.
Employees
188
Headquarters
Dublin 2, Ireland
CEO
Mr. Gregory J. Divis Jr.
Latest News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg